Abstract
Excitatory amino acids act via receptor subtypes in the mammalian central nervous system (CNS)1–3. The receptor selectively activated by N-methyl-D-aspartic acid (NMDA) has been best characterized using voltage-clamp and single-channel recording; the results suggest that NMDA receptors gate channels that are permeable to Na+, K+ and other monovalent cations4–7. Various experiments suggest that Ca2+ flux is also associated with the activation of excitatory amino-acid receptors on vertebrate neurones8–11. Whether Ca2+ enters through voltage-dependent Ca2+ channels or through excitatory amino-acid-activated channels of one or more subtype is unclear. Mg2+ can be used to distinguish NMDA-receptor-activated channels from voltage-dependent Ca2+ channels, because at micromolar concentrations Mg2+ has little effect on voltage-dependent Ca2+ channels12 while it enters and blocks NMDA receptor channels4,5,7,13,14. Marked differences in the potency of other divalent cations acting as Ca2+ channel blockers compared with their action as NMDA antagonists also distinguish the NMDA channel from voltage-sensitive Ca2+ channels5,7. However, we now directly demonstrate that excitatory amino acids acting at NMDA receptors on spinal cord neurones increase the intracellular Ca2+ activity, measured using the indicator dye arsenazo III, and that this is the result of Ca2+ influx through NMDA receptor channels. Kainic acid (KA), which acts at another subtype of excitatory amino-acid receptor, was much less effective in triggering increases in intracellular free Ca2+.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Krogsgaard-Larsen, P., Honoré, T., Hansen, J. J., Curtis, D. R. & Lodge, D. Nature 284, 64–66 (1980).
Watkins, J. C. & Evans, R. H. A. Rev. Pharmac. Tox. 21, 165–205 (1981).
McLennan, H. Prog. Neurobiol. 20, 251–271 (1983).
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A. & Prochiantz, A. Nature 307, 462–465 (1984).
Mayer, M. L., Westbrook, G. L. & Guthrie, P. B. Nature 309, 261–263 (1984).
Mayer, M. L. & Westbrook, G. L. J. Physiol., Lond. 354, 29–53 (1984).
Mayer, M. L. & Westbrook, G. L. J. Physiol., Lond. 361, 65–90 (1985).
Dingledine, R. J. Physiol., Lond. 343, 385–405 (1983).
Bührle, C. P. & Sonnhof, U. Pflügers Arch. ges. Physiol. 396, 154–162 (1983).
Zanotto, L. & Heinemann, U. Neurosci. Lett. 35, 79–84 (1983).
Pumain, R. & Heinemann, U. J. Neurophysiol. 53, 1–16 (1985).
Lansman, J. B., Hess, P. & Tsien, R. W. J. gen. Physiol. (in the press).
Ault, B., Evans, R. H., Francis, A. S., Oakes, D. J. & Watkins, J. C. J. Physiol., Lond. 307, 413–428 (1980).
Crunelli, V. & Mayer, M. L. Brain Res. 311, 392–396 (1984).
Hamill, O. P., Marty, A., Neher, E., Sakmann, B. & Sigworth, F., Pflügers Arch. ges. Physiol. 391, 85–100 (1981).
Cull-Candy, S. G. & Ogden, D. C. Proc. R. Soc. B224, 367–373 (1985).
Hagiwara, S. & Bylerly, L. A. Rev. Neurosci. 4, 69–125 (1981).
Smith, S. J., MacDermott, A. B. & Weight, F. F. Nature 304, 350–352 (1983).
Gorman, A. L. F. & Thomas, M. V. J. Physiol., Lond. 308, 259–285 (1980).
Berridge, M. J. & Irvine, R. F. Nature 312, 315–321 (1984).
Sladeczek, F., Pin, J. P., Récasens, M., Bockaert, J. & Weiss, S. Nature 317, 717–719 (1985).
Schoffelmeer, A. M. N. & Mulder, A. H. J. Neurochem. 40, 615–621 (1983).
Evans, R. H. & Watkins, J. C. J. Physiol., Lond. 277, 57P (1977).
Nowak, L. M. & Ascher, P. Soc. Neurosci. Abstr. 10, 23 (1984).
Mayer, M. L. & Westbrook, G. L. Soc. Neurosci. Abstr. 11, 785 (1985).
Ascher, P. & Nowak, L. J. Physiol., Lond. Proc. (in the press).
Fabiato, A. & Fabiato, F. Ann. N.Y. Acad. Sci. 307, 491–522 (1978).
Nowak, L. M. & Ascher, P. Soc. Neurosci. Abstr. 11, 953 (1985).
Lynch, G., Larson, J., Kelso, S., Barrinuevo, G. & Schottler, F. Nature 305, 719–721 (1983).
Collingridge, G. L., Kehl, S. J. & McLennan, H. J. Physiol., Lond. 334, 33–46 (1983).
Parsons, R. L. in Calcium in Drug Action (ed. Weiss, G. B.) 289–314 (Plenum, New York, 1978).
Miledi, R. Proc. R. Soc. B209, 447–452 (1980).
Adams, D. J., Dwyer, T. M. & Hille, B. J. gen. Physiol. 75, 493–510 (1980).
Edwards, C. Neuroscience 7, 1335–1366 (1982).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
MacDermott, A., Mayer, M., Westbrook, G. et al. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature 321, 519–522 (1986). https://doi.org/10.1038/321519a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/321519a0
This article is cited by
-
Disease-associated nonsense and frame-shift variants resulting in the truncation of the GluN2A or GluN2B C-terminal domain decrease NMDAR surface expression and reduce potentiating effects of neurosteroids
Cellular and Molecular Life Sciences (2024)
-
Inhibition of the NMDA Currents by Probenecid in Amygdaloid Kindling Epilepsy Model
Molecular Neurobiology (2024)
-
Adaptive control of synaptic plasticity integrates micro- and macroscopic network function
Neuropsychopharmacology (2023)
-
Roles of Phosphorylation of N-Methyl-d-Aspartate Receptor in Chronic Pain
Cellular and Molecular Neurobiology (2023)
-
Mitochondrial function in spinal cord injury and regeneration
Cellular and Molecular Life Sciences (2022)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.